MCM
BMRN icon

Mason Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Mason Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,000
Closed -$302K – 36
2021
Q1 		$302K Buy
+4,000
New +$327K 0.07% 21

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Mason Capital Management's BMRN Position: Q2 2021 in Review

Mason Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2021, closing a stake of 4,000 shares — an estimated $302K sold.

Mason Capital Management first reported a position in BMRN in Q1 2021 and held it in 1 quarter. The position peaked at $302K in Q1 2021. 529 funds tracked by Wall St. Rank hold BMRN as of Q2 2021.

  • Mason Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Mason Capital Management sold 4,000 BioMarin Pharmaceuticals shares in Q2 2021, an estimated $302K.
  • Mason Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Mason Capital Management's BioMarin Pharmaceuticals position peaked at $302K in Q1 2021.
  • 529 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2021.

Based on Mason Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.